The AHA today commented on the Food and Drug Administration’s draft guidance for industry and FDA staff on clinical decision support software as part of the agency’s efforts to implement Section 3060(a) of the 21st Century Cures Act. AHA expressed concern that “FDA’s interpretation of certain criteria could result in many existing CDS algorithms being subject to the FDA approval process and ultimately slow the pace of innovation and development of new algorithms to support better patient care and outcomes.” In its letter, AHA shared specific recommendations with FDA and said it “looks forward to working with the FDA to ensure the agency’s regulatory approach to implementing Section 3060(a) is consistent with the language and intent of the Cures Act and prioritizes patient safety while at the same time allowing hospitals and health systems to continue to implement innovative decision support tools.”

Related News Articles

Headline
The AHA’s American Society for Health Care Engineering last week presented its 2021 Crystal Eagle Leadership Award to Timothy Eugene Adams, program director…
Headline
Read a recap and insights from health care leaders during AHA’s July 15 webinar, “Addressing COVID-19 Vaccine Hesitancy in Your Community,” featuring messaging…
Headline
Learn how hospital and health system leaders such as Jonathan Perlin, M.D., president of clinical operations and chief medical officer at HCA Healthcare, are…
Headline
Alison Brisson, a member of AHA’s American Society for Health Care Engineering affiliate and director of facilities at Concord Hospital in New Hampshire,…
#HealthCareInnovation Thursday Blog
At M Health Fairview in Minnesota, we’ve created a unique approach to emergency mental health care by using thoughtful design with evidence-based techniques…
Headline
In this AHA blog Priya Bathija, vice president of strategic initiatives, and Elisa Arespacochaga, vice president of clinical affairs and workforce, share…